At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Creatine monohydratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD
In Brief
A Phase 2 clinical trial evaluating Creatine monohydrate for Huntington's Disease (HD). Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease (HD)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedAug 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedAug 9, 2011
Enrollment StartApr 1, 2005
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 14.9 years ago
Interventions
Creatine monohydratedrug
Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose